



8/21/06 | Press Release

**DAVA Pharmaceuticals, Inc. Announces  
Completion of Acquisition of STADA, Inc.**

Fort Lee, New Jersey, August 21, 2006 – DAVA Pharmaceuticals, Inc. (“DAVA”) announced today that it has completed the acquisition of STADA, Inc., which owns and operates the U.S. pharmaceutical business of German pharmaceutical leader STADA Arzneimittel AG.

“With the completion of this acquisition, DAVA has made significant progress towards achieving its goal of offering a diverse portfolio of products to its customers” said John H. Klein, Chairman and Chief Executive Officer of DAVA. Aram Moezinia, DAVA’s Executive Vice President of Global Business Development added, “DAVA is pleased to have completed the STADA acquisition and to have added such a robust product development pipeline to DAVA’s current product portfolio.”

DAVA has assumed the operations of STADA, Inc. under the DAVA Pharmaceuticals name as of August 22, 2006.

About DAVA Pharmaceuticals, Inc.

DAVA Pharmaceuticals, Inc., a specialty pharmaceutical company, is focused on establishing and marketing a broad portfolio of pharmaceutical products. DAVA Pharmaceuticals is aggressively building its product portfolio through a combination of acquisitions, strategic alliances, in-licensing transactions, partnerships and development. For further information, please visit [www.davapharma.com](http://www.davapharma.com).